Skip to content
Screener

Opus Genetics IRD Total Equity

Total Equity at other companies

AbbVie logo
AbbVieABBV
-$6.66B-569%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
-$58.13M-276%
Regenxbio logo
RegenxbioRGNX
$71.77M-66.4%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$451.84M-3.8%
Opko Health logo
Opko HealthOPK
$1.18B-8.7%
uniQure logo
uniQureQURE
$324.05M+8,195%

Other financials

Income statement

See full
Revenue$2.2M-50.6%
Operating income-$14.4M-44.7%
Net income-$65.5M-700%
EPS (diluted)-$0.75-213%

Balance sheet

See full
Cash & equivalents$60.0M+43.5%
Total debt$1.2M
Total assets$66.8M+38.7%

Cash flow

See full
Operating cash flow-$12.7M-41.5%

Valuation

See full
Market cap$304.5M+381%
Enterprise value$245.74M+672%
P/S25.4×+21.3×

Profitability

See full
Operating margin-359.1%-68.9pp
Net margin-892.4%-12,322pp

Returns & leverage

See full
Return on equity-449.4%-2,573pp
Debt / equity0.1×
Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Opus Genetics’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:03 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-034084
AssetsAs of / March 31,2026 / (Unaudited)As of / December 31,2025
Series B preferred stock, par value $0.0001; 7,374,632 shares and no shares were designated as of March 31, 2026 and December 31, 2025, respectively; 7,374,632 shares and no shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively.24,736
Stockholders’ (deficit) equity:
Preferred stock, par value $0.0001; 2,625,368 shares and 10,000,000 shares authorized as of March 31, 2026 and December 31, 2025, respectively; no shares issued and outstanding at March 31, 2026 and December 31, 2025.
Common stock, par value $0.0001; 125,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 71,402,472 and 69,894,507 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively.77
Additional paid-in capital208,281203,930
Accumulated deficit(254,124)(188,589)
Total stockholders’ (deficit) equity(45,836)15,348
Total liabilities, convertible preferred stock and stockholders’ (deficit) equity$66,787$50,243

Item 1. Financial Statements

FAQ

What is Opus Genetics's total equity?
Opus Genetics (IRD) reported total equity of -$45.84M in Q1 2026.
How has Opus Genetics's total equity changed year-over-year?
Opus Genetics's total equity decreased by 1003.5% year-over-year, from $5.07M to -$45.84M.
What is the long-term trend for Opus Genetics's total equity?
Over 5 years (2020 to 2025), Opus Genetics's total equity has grown at a 2.6% compound annual growth rate (CAGR), from -$13.47M to $15.35M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Opus Genetics's total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude